GlucoModicum unveiled Sofio, which it labels the world’s first needle-free glucose monitor based on magneto-hydrodynamics (MHD).
MHD technology draws micro-samples of interstitial fluid through the skin. It measures glucose with established electrochemical sensor technology. The single-day sensor system delivers a periodic, personalized monitoring alternative to standard continuous glucose monitor (CGM) devices.
Related: Tuodao Medical launches with surgical robot technology
Helsinki, Finland-based GlucoModicum’s method, like existing CGMs from Abbott and Dexcom, measures glucose through established glucose oxidase enzyme chemistry. However, the company aims to offer an option for people who don’t require 24/7 monitoring.
GlucoModicum said it developed Sofio with the idea in mind that type 2 diabetes “is not static.” With glucose patterns shifting alongside lifestyle, medication, genetics and age, the company said it wanted to provide an option for people with type 2 diabetes who don’t need a sensor attached to them for weeks at a time.
Sofio enables single-day glucose monitoring sessions with deeper insights when needed. That includes during dietary or lifestyle changes, medication adjustments or periodic checkups.
The system features a durable, rechargeable transmitter that lasts up to two years. It has a gentle, replaceable single-day sensor for those looking to avoid continuous wear.
Clinical study data previously demonstrated accuracy in line with regulatory expectations for interstitial glucose monitoring. Earlier this year, the company reported a mean absolute relative difference (MARD, a measure of CGM accuracy) of 11.5%. This approaches the industry benchmark of 10% set by needle-based CGM, the company says.
GlucoModicum said it engineered Sofio for mass manufacturability and established production partnerships for the device. It plans to progress through European regulatory pathways soon, with further updates — including related to its U.S. and FDA strategy — set to come in 2026.
“Needle-free glucose monitoring has been one of the most elusive goals in diabetes management for over thirty years,” said Jokke Mäki, CEO of GlucoModicum. “Our MHD-based approach takes a different route, enabling accurate glucose measurement without needles while relying on the established biosensing chemistry used in clinical devices.”
